Sarepta Therapeutics To Join S&P Midcap 400, Effective June 3
Portfolio Pulse from Benzinga Newsdesk
Sarepta Therapeutics (SRPT) will join the S&P MidCap 400, replacing Shockwave Medical (SWAV) effective June 3. Johnson & Johnson (JNJ) is acquiring Shockwave Medical, with the deal expected to close soon.
May 29, 2024 | 9:20 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Shockwave Medical will be replaced by Sarepta Therapeutics in the S&P MidCap 400 due to its acquisition by Johnson & Johnson.
Shockwave Medical's removal from the S&P MidCap 400 is a result of its acquisition by Johnson & Johnson. The stock price impact is neutral as the acquisition is already priced in.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
Johnson & Johnson is acquiring Shockwave Medical, which will result in Shockwave being replaced by Sarepta Therapeutics in the S&P MidCap 400.
The acquisition of Shockwave Medical by Johnson & Johnson is a strategic move that could enhance JNJ's portfolio, potentially leading to a positive short-term impact on JNJ's stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 80
POSITIVE IMPACT
Sarepta Therapeutics will join the S&P MidCap 400, which could increase its visibility and attract more institutional investors.
Joining the S&P MidCap 400 can lead to increased visibility and potentially more investment from institutional investors, which could positively impact the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100